Author:
Lamotte Guillaume,Millar Vernetti Patricio
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),Endocrine and Autonomic Systems
Reference14 articles.
1. Biopharma (Theravance Biopharma) (2021) Press release: Thervance Biopharma Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension. https://www.prnewswire.com/news-releases/theravance-biopharma-inc-announces-top-line-results-from-a-phase-3-study-of-ampreloxetine-in-patients-with-symptomatic-neurogenic-orthostatic-hypotension-301377200.html
2. De Martini D (2020) Empowering phase 2 clinical trials to reduce phase 3 failures. Pharm Stat 19:178–186
3. De Pablo-Fernandez E, Tur C, Revesz T, Lees AJ, Holton JL, Warner TT (2017) Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol 74:970–976
4. Fanciulli A, Campese N, Goebel G, Ndayisaba JP, Eschlboeck S, Kaindlstorfer C, Raccagni C, Granata R, Bonuccelli U, Ceravolo R, Seppi K, Poewe W, Wenning GK (2020) Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. Neurology 95:e2854–e2865
5. Kaufmann H, Vickery R, Wang W, Kanodia J, Shibao CA, Norcliffe-Kaufmann L, Haumann B, Biaggioni I (2021) Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clin Auton Res (online ahead of print)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献